I work at amgen. ask me anthing. I'll answer honestly







Dude, is this seriously something worth caring about? Calm down. No one is assuming that the OP is the only one who knows anything, nor are they assuming that any comment claiming to be the OP really is. Chill.


It's just so annoying. It's like she or he controls the thread. Who cares if it's the O/P answering the questions or not.? I've just never seen anything like his. People start threads all the time, they don't keep saying "O/P here". the "real O/P" and all are trolls who are not the O/P. NO, we are NOT all trolls if we are not the "O/P". Just stop
 






It's just so annoying. It's like she or he controls the thread. Who cares if it's the O/P answering the questions or not.? I've just never seen anything like his. People start threads all the time, they don't keep saying "O/P here". the "real O/P" and all are trolls who are not the O/P. NO, we are NOT all trolls if we are not the "O/P". Just stop
Real OP here. I agree with you about all of the trolls. So everyone will know that it's me, I will end each post with "4 touchdowns at Polk High."

4 touchdowns at Polk High
 












It's just so annoying. It's like she or he controls the thread. Who cares if it's the O/P answering the questions or not.? I've just never seen anything like his. People start threads all the time, they don't keep saying "O/P here". the "real O/P" and all are trolls who are not the O/P. NO, we are NOT all trolls if we are not the "O/P". Just stop


I promise that you are MORE annoying coming on here whining about someone writing “OP”. WAY more annoying…and I am not the OP.
 






OP here... the Chemocentryx employees that were let go are in roles that we already have people for. This is to be expected in any buyout. The sales reps for the most part are safe. I expect the same for Horizon.
 












OP here... the Chemocentryx employees that were let go are in roles that we already have people for. This is to be expected in any buyout. The sales reps for the most part are safe. I expect the same for Horizon.

Ok, we are looking for specifics here. Did ANYONE in sales or sales management get laid off? We are trying to understand if they just took the territories/sales reps as is or if they analyzed them with ZS or whoever they use & made some adjustments to the sales force.
 






OP here... the Chemocentryx employees that were let go are in roles that we already have people for. This is to be expected in any buyout. The sales reps for the most part are safe. I expect the same for Horizon.

Amgen does not draw specialty lines when it comes to promoting. Krystexxa will need to combine neph/rheum and thin the ranks. Ophthalmology will need to change management lines. Having all the managers live in New York makes zero sense.
 






Ok, we are looking for specifics here. Did ANYONE in sales or sales management get laid off? We are trying to understand if they just took the territories/sales reps as is or if they analyzed them with ZS or whoever they use & made some adjustments to the sales force.

OP here again- like I previously said I heard no sales or managers got let go. I don't expect any in eye or neuro to get let go with Horizon. I would expect some cuts to the gout team as you have 2 reps covering each territory- and I heard even more than 2 in some territories. But we will likely go with smaller territories so it won't be anywhere near 50% cut. Also we have a strong nephrology pipeline coming so I'd expect cuts to weighted towards Rheumatology since we also have those reps (ie. we will need less of your guys). Fortunately those that are cut will be taken care of I heard you have quite a few RSU's.
 






OP here again- like I previously said I heard no sales or managers got let go. I don't expect any in eye or neuro to get let go with Horizon. I would expect some cuts to the gout team as you have 2 reps covering each territory- and I heard even more than 2 in some territories. But we will likely go with smaller territories so it won't be anywhere near 50% cut. Also we have a strong nephrology pipeline coming so I'd expect cuts to weighted towards Rheumatology since we also have those reps (ie. we will need less of your guys). Fortunately those that are cut will be taken care of I heard you have quite a few RSU's.


Again, just asking for actual facts regarding what happened with Chemocentryx, not speculation on what will happen to us.
This should be closed in 60 days, since the Scheme meeting date was announced today, so we will find out our fate soon enough.
 












Amgen does not draw specialty lines when it comes to promoting. Krystexxa will need to combine neph/rheum and thin the ranks. Ophthalmology will need to change management lines. Having all the managers live in New York makes zero sense.


And Amgen hasn’t had a situation w/ a buy and bill drug rare disease drug with 2 separate sales forces, so you know nothing. Plus, they have a derm & rheum forces for the same drug, so, yeah, they draw specialty lines.
I think they should combine & shrink territories, but what Amgen has done historically is irrelevant.
 










































And Amgen hasn’t had a situation w/ a buy and bill drug rare disease drug with 2 separate sales forces, so you know nothing. Plus, they have a derm & rheum forces for the same drug, so, yeah, they draw specialty lines.
I think they should combine & shrink territories, but what Amgen has done historically is irrelevant.

OP here...we are not considering Krystexxa "rare disease" (regardless of the official classification from the FDA). Nothing is decided yet that I know of- but I'm hearing they will be making territories smaller with some rep displacement. Most displacement will come from Rheumatology side. Reason being they (people making the decisions- not me) feel we will need nephrology experience for potential new products. I'm good friends with one of the people making the decisions. Some of the Rheum reps may be rolled into other divisions like cardio and bone health.

I'm here to help. Sorry for all the trolling.